Comparison of cell-surface TFPIα and β

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 12, 2005, Pages 2677-2683

  Piro, O ^a   Broze Jr , G J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hematology   (United States)

Author keywords

Coagulation; Endothelium derived factors; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; INTERLEUKIN 1; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN TISSUE FACTOR PATHWAY INHIBITOR ALPHA; PROTEIN TISSUE FACTOR PATHWAY INHIBITOR BETA; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTICOAGULATION; ARTICLE; CELL SURFACE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS;

ANIMALS; ANTIGENS, SURFACE; CELL LINE; GENE EXPRESSION PROFILING; GLYCOSYLATION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; LIPOPOLYSACCHARIDES; LIPOPROTEINS; N-ACETYLNEURAMINIC ACID; PROTEIN ISOFORMS; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 29244478620     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01636.x     Document Type: Article

References (25)

1. Broze GJ Jr. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 1992; 29: 159-69.
2. Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard JJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-43.
3. Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor (TFPI) gene. Thromb Haemost 1999; 81: 45-9.
4. Zhang J, Piro O, Lu L, Broze GJ Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003; 108: 623-7.
5. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ Jr. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 1988; 263: 6001-4.
6. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-20.
7. Petersen LC, Bjorn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Eur J Biochem 1996; 235: 310-6.
8. Piro O, Broze GJ Jr. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding. Circulation 2004; 110: 3567-72.
9. Lindhout T, Franssen J, Willems G. Kinetics of the inhibition of tissue factor-factor VIIa by tissue factor pathway inhibitor. Thromb Haemost 1995; 74: 910-5.
10. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proc Natl Acad Sci USA 1990; 87: 8869-73.
11. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
12. Mast AE, Acharya N, Malecha MJ, Hall CL, Dietzen DJ. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol 2002; 22: 2099-104.
13. Hansen JB, Svensson B, Olsen R, Ezban M, Osterud B, Paulssen RH. Heparin induces synthesis and secretion of tissue factor pathway inhibitor from endothelial cells in vitro. Thromb Haemost 2000; 83: 937-43.
14. Lupu C, Poulsen E, Roquefeuil S, Westmuckett AD, Kakkar VV, Lupu F. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture. Arterioscler Thromb Vasc Biol 1999; 19: 2251-62.
15. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
16. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: regulation by cytosolic calcium. Proc Natl Acad Sci USA 1990; 87: 6995-6999.
17. Walsh JD, Geczy CL. Discordant expression of tissue factor antigen and procoagulant activity on human monocytes activated with LPS and low dose cycloheximide. Thromb Haemost 1991; 66: 552-558.
18. Wolberg AS, Monroe DM, Roberts HR, Hoffman MR. Tissue factor de-encryption: Ionophore treatment induces changes in tissue factor activity by phosphatidyserine-dependent and -independent mechanisms. Blood Coagul. Fibrinolysis 1999; 10: 201-210.
19. Broze GJ Jr, Lange GW, Duffin KL, MacPhail L. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
20. Nakahara Y, Miyata T, Hamuro T, Funatsu A, Miyagi M, Tsunasawa S, Kato H. Amino acid sequence and carbohydrate structure of a recombinant human tissue factor pathway inhibitor expressed in Chinese hamster ovary cells: one N- and two O-linked carbohydrate chains are located between Kunitz domains 2 and 3 and one N-linked carbohydrate chain is in Kunitz domain 2. Biochemistry 1996; 35: 6450-9.
21. Smith PL, Skelton TP, Fiete D, Dharmesh SM, Beranek MC, MacPhail L, Broze GJ Jr, Baenziger JU. The asparagine-linked oligosaccharides on tissue factor pathway inhibitor terminate with SO4-4GalNAc beta 1, 4GlcNAc beta 1,2 Mana alpha. J Biol Chem 1992; 267: 19140-6.
22. Piro O, Broze GJ Jr. Comparison of the structure, binding, and activity of cell surface TFPIα and TFPIβ. Blood 2004; 104: 66a, abstract219.
23. Ho G, Narita M, Broze GJ Jr, Schwartz AL. Recombinant full-length tissue factor pathway inhibitor fails to bind to the cell surface: implications for catabolism in vitro and in vivo. Blood 2000; 95: 1973-8.
24. Ahamed J, Belting M, Ruf W. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor-1. Blood 2005; 105: 2384-91.
25. Kamikubo Y, Hamuro T, Matsuda J, Kamei S, Jyu-ri K, Miyamoto S, Funatsu A, Kato H. The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h-rTFPI with factor Xa promotes a clearance rate of h-rTFPI. Thromb Res 1996; 83: 161-73.